Get started
Author

Sophie G. Carlson

Observed names: Sophie Carlson, Sophie G Carlson
ORCID: 0009-0007-6686-1494
Observed ORCID: 0009-0007-6686-1494
OpenAlex ID: A5072955574
Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer
2019 · Anthony D. Saleh, Hui Cheng, et al. · Clinical Cancer Research · 87
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
2015 · Suresh Mohan, Robert Vander Broek, et al. · Clinical Cancer Research · 69
SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2
2016 · Danielle F. Eytan, Grace E. Snow, et al. · Cancer Research · 67
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
2023 · Ajay Major, Jovian Yu, et al. · Blood Advances · 41
PDF
Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC
2014 · Danielle F. Eytan, Grace E. Snow, et al. · The Laryngoscope · 29
Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2024 · Ethan L. Morgan, Anthony D. Saleh, et al. · Cancer Research Communications · 5
PDF
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
2021 · Yi An, Jun Jeon, et al. · Scientific Reports · 5
PDF
Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma
2025 · Sophie Carlson, Tasha L. Lin, et al. · Immunotherapy · 3
Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
2022 · Ajay Major, Jovian Yu, et al. · Blood · 3
Abstract 3821: Targeted therapy for head and neck squamous cell carcinoma using the novel SMAC-mimetic birinapant
2016 · Adeeb Derakhshan, Danielle Eytan, et al. · Cancer Research · 3
Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) on Treatment Outcomes in Multiple Myeloma Patients Undergoing CAR-T Cell Therapy.
2025 · Sophie G Carlson, Benjamin Puliafito, et al. · Transplantation and Cellular Therapy · 2
Rethinking the possibilities of adult ring sideroblastic anaemia
2026 · Sophie G Carlson, Matthew Koo, et al. · The Lancet Haematology
PA-445 Single Center, Real World Data Exploring the Impact of Extramedullary Disease and CHIP on the Risk of Non-ICANS Neurotoxicity
2026 · Sophie G. Carlson, Maryam Hajiabbasi, et al. · Clinical Lymphoma Myeloma & Leukemia
Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy
2026 · Sophie G. Carlson, Benjamin R. Puliafito, et al. · International Journal of Hematology
PDF
Figure S10 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Table S5 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Figure S8 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Figure S1 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Supplementary Methods from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Table S1-5 legends from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Table S1 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Figure S9 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Figure S7 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Figure S4 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Table S2 from Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma
2026 · Ethan L. Morgan, Anthony D. Saleh, et al.
Works count: 105
Citation count: 314
H-index: 5
I10-index: 5
Year
Topic
Type